A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.
Kavanagh
J J
JJ
Copeland
L J
LJ
Gershenson
D M
DM
Saul
P B
PB
Edwards
C L
CL
D000328:Adult; D000368:Aged; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D015255:Idarubicin; D003630:Daunorubicin